Systems and methods for incorporating co-formulations of insulin in an automatic insulin delivery system
Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
1. A method comprising:
calculating a quantity of a first drug that has been delivered to a user within a most recent predetermined period of time, wherein the first drug is GLP-1;
calculating a correction factor used in the calculation of a dose of insulin to be delivered to the user;
calculating a modified correction factor based on the calculated correction factor and the calculated quantity of the first drug that has been delivered to the user;
calculating a dose of insulin to be delivered to the user based on the modified correction factor, wherein calculating the dose of insulin comprises:
determining an insulin to carbohydrate (I:C) ratio used in the calculation of the dose of insulin to be delivered to the user,
calculating a modified I:C ratio based on the calculated quantity of GLP-1 that has been delivered to the user, and
calculating the dose of insulin to be delivered to the user based on the modified I:C ratio; and
delivering the calculated dose of insulin to the user;
wherein the calculated dose of insulin delivered to the user is delivered as a co-formulation of the first drug and insulin.
2. The method of claim 1 wherein, when the bolus doses are being delivered to the user, the method further calculates the quantity of GLP-1 that has been delivered to a user, accounting for expected changes in insulin sensitivity of the user due to additional GLP-1 that is delivered.
3. The method of claim 1 wherein calculating a modified correction factor and I:C ratio assumes an average effect of the delivery of the GLP-1 in the co-formulation on the insulin sensitivity of a population of users.
4. A system comprising:
a drug delivery device configured to deliver a co-formulation of insulin and a second drug to a user; and
an algorithm, implemented by software executed by a processor, to determine the timing and quantity of the delivery of the co-formulation of insulin and the second drug to the user, wherein the algorithm:
calculates a quantity of the second drug that has been delivered to a user within a most recent predetermined period of time, wherein the first drug is GLP-1;
calculates a correction factor used in the calculation of a dose of insulin to be delivered to the user;
calculates a modified correction factor based on the calculated correction factor and the calculate quantity of the second drug that has been delivered to the user; and
calculates a dose of insulin to be delivered to the user based on the modified correction factor, wherein calculating the dose of insulin comprises:
determining an insulin to carbohydrate (I:C) ratio used in the calculation of the dose of insulin to be delivered to the user,
calculating a modified I:C ratio based on the calculated quantity of GLP-1 that has been delivered to the user, and
calculating the dose of insulin to be delivered to the user based on the modified I:C ratio; and
wherein the drug delivery device delivers the calculated dose of insulin to the user.
5. The system of claim 4 wherein, when the bolus doses are being delivered to the user, the algorithm further calculates the quantity of the second drug that has been delivered to a user, accounting for expected changes in insulin sensitivity of the user due to additional amount of the second drug that is delivered.